Literature DB >> 23466804

Reevaluation of sst₁ somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-7.

Amelie Lupp1, Falko Nagel1, Stefan Schulz2.   

Abstract

BACKGROUND: The somatostatin receptor 1 (sst1) is widely distributed throughout the body and is also present in neoplastic tissues. However, little is known about its precise tissue distribution, regulation and function, which may in part be due to the lack of specific monoclonal anti-sst1 antibodies.
METHODS: We have characterized the novel rabbit monoclonal anti-human sst1 antibody UMB-7 using sst1-expressing cells and human pituitary samples. The antibody was then used for immunohistochemical staining of a large panel of formalin-fixed, paraffin-embedded human tissues.
RESULTS: Western blot analyses of BON-1 cells and human pituitary revealed a broad band migrating at a molecular weight of 45,000-60,000. After enzymatic deglycosylation the size of this band decreased to a molecular weight of 45,000. UMB-7 yielded an efficient immunostaining of distinct cell populations in the human tissue samples with a predominance of plasma membrane staining, which was completely abolished by preadsorption of UMB-7 with its immunizing peptide. The sst1 receptor was detected in anterior pituitary, pancreatic islets, distal tubules, enteric ganglion cells and nerve fibers, chief cells of the gastric mucosa, macrophages and mast cells. In addition, sst1 was observed in pituitary adenomas, gastrointestinal neuroendocrine tumors and pheochromocytoma as well as in pancreatic adenocarcinomas, gastric carcinomas, urinary bladder carcinomas and sarcomas.
CONCLUSIONS: UMB-7 may prove of great value in the identification of sst1-expressing tumors during routine histopathological examinations. This may open up new routes for diagnostic and therapeutic intervention.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23466804     DOI: 10.1016/j.regpep.2013.02.001

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  15 in total

Review 1.  Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5.

Authors:  Stefan Schulz; Andreas Lehmann; Andrea Kliewer; Falko Nagel
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 2.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

3.  Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours.

Authors:  Ylberta Kajtazi; Daniel Kaemmerer; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-26       Impact factor: 4.553

4.  Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.

Authors:  Thomas Günther; Michael Culler; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2016-03-11

5.  Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies.

Authors:  Max Czajkowski; Daniel Kaemmerer; Jörg Sänger; Guido Sauter; Ralph M Wirtz; Stefan Schulz; Amelie Lupp
Journal:  BMC Cancer       Date:  2022-07-07       Impact factor: 4.638

6.  Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer.

Authors:  Claudia Stumpf; Daniel Kaemmerer; Elisa Neubauer; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

7.  Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin.

Authors:  Susann Stollberg; Daniel Kämmerer; Elisa Neubauer; Stefan Schulz; Ingrid Simonitsch-Klupp; Barbara Kiesewetter; Markus Raderer; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-20       Impact factor: 4.553

8.  Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade I-IV astrocytic brain tumors.

Authors:  Franziska Lange; Daniel Kaemmerer; Julianne Behnke-Mursch; Wolfgang Brück; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2018-04-25       Impact factor: 4.553

9.  Immunohistochemical Expression of Somatostatin Receptor Subtypes in a Panel of Neuroendocrine Neoplasias.

Authors:  Satu M Remes; Helena L Leijon; Tiina J Vesterinen; Johanna T Arola; Caj H Haglund
Journal:  J Histochem Cytochem       Date:  2019-06-10       Impact factor: 2.479

10.  Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.

Authors:  Daniel Kaemmerer; Tina Träger; Maike Hoffmeister; Bence Sipos; Merten Hommann; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  Oncotarget       Date:  2015-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.